This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
IDEXX Laboratories (IDXX) Beats on Q4 Revenues, View Up
by Zacks Equity Research
IDEXX Laboratories (IDXX) gains on solid contributions from Companion Animal Group business in Q4.
Medical Device Stocks Earnings Due on Feb 1: BSX, BAX & More
by Zacks Equity Research
As part of the amended tax policy, corporate tax rates are lowered to 21% from 35%, offering a huge relief to medical device giants.
Can IDEXX (IDXX) Post a Beat in Q4 Earnings on CAG Strength?
by Zacks Equity Research
IDEXX Laboratories (IDXX) is poised to gain from strength in CAG Diagnostics business in Q4.
IDEXX Launches Catalyst SDMA for Veterinary Renal Disorder
by Zacks Equity Research
IDEXX Laboratories (IDXX) already puts its Catalyst SDMA Test to use for hundreds of medical practices across the United States.
5 Reasons Why You Should Buy Baxter (BAX) Stock Right Now
by Zacks Equity Research
Baxter (BAX) has been gaining on the back of favorable developments in the regulatory front and product launches.
Intuitive Surgical Banks on da Vinci X, Forex Woes Remain
by Zacks Equity Research
Intuitive Surgical's (ISRG) consistent efforts to boost da Vinci X platform is a positive. However, foreign exchange movements are impacting the company's results
6 MedTech Stocks Set to Crush the Market in 2018
by Zacks Equity Research
Here we take a peek at six MedTech stocks that are expected to post stellar returns in 2018.
Ecolab, Cargill and Techstars Launch Accelerator Program
by Zacks Equity Research
Ecolab (ECL) continues to focus on investment in key businesses and bolt-on acquisitions to gain market traction and boost profits.
Here's Why You Should Invest in PetMed (PETS) Stock Now
by Zacks Equity Research
PetMed's (PETS) implements strategies to revitalize top line. It also offers a comprehensive portfolio.
IDEXX Laboratories Banks on Global Prospects, CAG Strength
by Zacks Equity Research
IDEXX Laboratories (IDXX) rides on strength across all segments, especially CAG. Strong fundamentals buoy optimism.
Ecolab Focuses on Pest Elimination, Acquires 3 Companies
by Zacks Equity Research
Ecolab (ECL) continues to focus on investment in key growth businesses and bolt-on acquisitions to gain market traction and boost profits and inorganic growth.
Zacks.com highlights: Chemed, Baxter International, IDEXX Laboratories, Advanced Energy Industries and Pioneer Natural Resources
by Zacks Equity Research
Zacks.com highlights: Chemed, Baxter International, IDEXX Laboratories, Advanced Energy Industries and Pioneer Natural Resources
5 of the Most Efficient Stocks to Boost Your Portfolio
by Tirthankar Chakraborty
Company with a favorable efficiency level generally provides impressive returns as it is believed to be positively correlated with the stock's price performance.
Here's Why You Should Invest in Baxter (BAX) Stock Right Now
by Zacks Equity Research
Baxter has witnessed favorable tidings on the regulatory front. The company enjoys strong presence in foreign markets.
Varian's Partners Penn Medicine, Proton Therapy in Focus
by Zacks Equity Research
Varian Medical's (VAR) solid prospects on the proton therapy space holds promise at the moment.
Stryker Gains Ground on MAKO Robotic Unit Amid Forex Woes
by Zacks Equity Research
Solid performance by the MAKO robotic platform has been boosting Stryker's (SYK) revenues for long.
Looking for a Growth Stock? Why It is Time to Focus on IDEXX Laboratories (IDXX)
by Zacks Equity Research
IDEXX Laboratories (IDXX) is seeing solid earnings estimate revision and has a favorable Zacks rank, making it well positioned for future earnings growth.
The Zacks Analyst Blog Highlights: IDEXX Laboratories, Luminex, Masimo, Align Technology and Cooper Companies
by Zacks Equity Research
The Zacks Analyst Blog Highlights: IDEXX Laboratories, Luminex, Masimo, Align Technology and Cooper Companies
5 MedTech Stocks to Beat Tax Hazards With Positive Returns
by Zacks Equity Research
Trump's tax reform policies promise to cut corporate taxes. However, the future of the U.S. MedTech industry depends on the much-awaited decision on the 2.3% medical device tax.
Medtronic (MDT) Beats on Q2 Earnings, Reiterates FY18 View
by Zacks Equity Research
Medtronic (MDT) rides high on strength in major business segments in Q2.
Patterson Companies (PDCO) Misses on Q2 Earnings, Cuts View
by Zacks Equity Research
Patterson Companies (PDCO) missed estimates for both the counts in Q2. A downbeat guidance indicates looming concerns.
Accelerate Diagnostics (AXDX) in Focus: Stock Moves 6.7% Higher
by Zacks Equity Research
Accelerate Diagnostics (AXDX) was a big mover last session, as the company saw its shares rise nearly 7% on the day.
Zacks.com highlights: Home Depot, Baxter International, IDEXX Laboratories, NVR and MAM Software Group
by Zacks Equity Research
Zacks.com highlights: Home Depot, Baxter International, IDEXX Laboratories, NVR and MAM Software Group
5 of the Most Efficient Stocks to Buy Now
by Tirthankar Chakraborty
We have considered four popular ratios in order to find efficient companies that have the potential to provide impressive returns.
DaVita Issues Downbeat '17 View, Hurricanes Affect Q3 Results
by Zacks Equity Research
Hurricanes Harvey and Irma dealt a heavy blow to DaVita's (DVA) operating income in the third quarter. Management's tepid forecast for the full year adds to the concerns.